# Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

> **NCT04895410** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 8 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Lemzoparlimab
- **DRUG:** Dexamethasone
- **DRUG:** Carfilzomib
- **DRUG:** Pomalidomide
- **BIOLOGICAL:** Daratumumab

## Key facts

- **NCT ID:** NCT04895410
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-17
- **Primary completion:** 2022-06-24
- **Final completion:** 2022-06-24
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04895410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04895410, "Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04895410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*